Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.

Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.

Service

Funding, debt advisory & ECM

Parties

“The COVID-19 pandemic has clearly highlighted the challenges and gaps in our industry in Europe. It makes our mission to make scarce medicines available more important than ever. We want to respond to this situation strongly by growing organically as well as through acquisitions in Europe. With the capital, the know-how and the broad (international) network of Gilde Buy Out Partners, Gilde Healthcare, and our existing investor Quadrum Capital, we can achieve this in both a socially responsible as well as financially sound manner.”

Jan Willem Popma

Director, Ace Pharmaceuticals BV

Talk to the deal team

Bas Stoetzer

Partner

Amsterdam, Netherlands
Oaklins Netherlands

View profile Get in touch

Niels Vermuë

Associate Director

Amsterdam, Netherlands
Oaklins Netherlands

View profile Get in touch

Related deals

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more

Armira has signed an agreement to acquire a majority stake in Viabus

Private Equity | Consumer & Retail

Armira has signed an agreement to acquire a majority stake in Viabus

Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.

Learn more

Triscan has joined APA and Riverarch to accelerate growth in the European aftermarket

Private Equity | Automotive

Triscan has joined APA and Riverarch to accelerate growth in the European aftermarket

Triscan AS, a leading provider of OE-quality automotive spare parts for the professional aftermarket in Europe, has been acquired by APA Industries, LLC, a portfolio company of Riverarch Equity Partners.

Learn more